{
  "input": {
    "mode": "init",
    "query": {
      "entity": "Atypical haemolytic uraemic syndrome",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_eculizumab",
          "name": "Eculizumab"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_ravulizumab",
          "name": "Ravulizumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_c5_inhibitor",
          "name": "C5 Inhibitor"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_complement_inhibitor",
          "name": "Complement Inhibitor"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_atacicept",
          "name": "Atacicept"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_efgartigimod",
          "name": "Efgartigimod"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_ishmael",
          "name": "Ishmael"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_aixin",
          "name": "Aixin"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_c1_inhibitor",
          "name": "C1 Inhibitor"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_pandemic_influenza_vaccine",
          "name": "Pandemic Influenza Vaccine"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_anti_c5_monoclonal_antibody",
          "name": "Anti-C5 Monoclonal Antibody"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_lixisenatide",
          "name": "Lixisenatide"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 1
    },
    "budgets": {
      "round_limit": 3,
      "token_limit": 200000
    },
    "heuristic_priors": [
      {
        "when": "general biomedical reasoning",
        "then": "区分短期表型与长期结局；明确潜在风险链"
      }
    ],
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "plan": {
      "rounds": 3,
      "graph_expectations": [
        "分析 C5 抑制剂及其对典型及非典型溶血性尿毒症综合症的可能作用机制",
        "补充与候选药物相关的支持性证据及潜在安全性风险"
      ],
      "scoring_weights": {
        "mechanism_fit": 0.3,
        "class_prior": 0.2,
        "pk_pd_feasibility": 0.2,
        "indication_plausibility": 0.2,
        "safety_risk": 0.1,
        "graph_bonus": 0.1,
        "conflict_penalty": 0.1
      },
      "stopping": {
        "max_rounds": 3,
        "delta_threshold": 0.03,
        "saturation_ratio": 0.65
      },
      "seed_policy": {
        "default": "conservative",
        "cooldown_rounds": 1,
        "max_regenerations": 1,
        "gate_thresholds": {
          "topk": 5,
          "min_disjointness": 2,
          "support_sum_max": 0.35,
          "conflict_over_support_ratio_min": 1.2
        },
        "required_prior_actions": [
          "add_mechanism_link",
          "add_outcome_nodes",
          "merge_claims"
        ]
      }
    }
  }
}